loxo-435 + pembrolizumab + enfortumab vedotin

This is a combination of three agents under evaluation primarily for the treatment of urothelial carcinoma. - **LOXO-435** is a small molecule selective inhibitor of fibroblast growth factor receptor 3 (FGFR3), developed for FGFR3-altered cancers, especially urothelial carcinoma. - **Pembrolizumab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), serving as an immune checkpoint inhibitor to activate T-cell responses against tumor cells. - **Enfortumab vedotin** is an antibody-drug conjugate targeting Nectin-4, highly expressed on urothelial carcinoma cells. It consists of a monoclonal antibody (enfortumab) linked to a cytotoxic agent (monomethyl auristatin E, MMAE), which disrupts microtubule assembly and induces apoptosis upon internalization[1][2][4][5]. This multi-agent combination is investigated to exploit synergy between FGFR3 blockade, immune checkpoint inhibition, and targeted cytotoxic delivery, mainly for metastatic or locally advanced urothelial carcinoma in clinical studies.

Brand names

Padcev (enfortumab vedotin)Keytruda (pembrolizumab)

Other names

enfortumab vedotin-ejfvAGS-22M6E (enfortumab vedotin)